[
  {
    "ts": "2026-01-07T01:08:18+00:00",
    "headline": "Is Johnson & Johnson (JNJ) Still Attractive After A 44% One Year Share Price Gain",
    "summary": "If you are wondering whether Johnson & Johnson shares still offer solid value after a strong run, this article will walk through what the current price might be implying about the company. The stock last closed at US$204.79, with returns of 1.4% over 30 days and 44.3% over 1 year, which may have changed how some investors think about both its potential and its risks. Over the past year, Johnson & Johnson has remained in focus as a large healthcare name. Investors have been watching how it...",
    "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-still-attractive-010818834.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "f8e748fc-eab1-3b33-8b3f-28a8274cc2d6",
      "content": {
        "id": "f8e748fc-eab1-3b33-8b3f-28a8274cc2d6",
        "contentType": "STORY",
        "title": "Is Johnson & Johnson (JNJ) Still Attractive After A 44% One Year Share Price Gain",
        "description": "",
        "summary": "If you are wondering whether Johnson & Johnson shares still offer solid value after a strong run, this article will walk through what the current price might be implying about the company. The stock last closed at US$204.79, with returns of 1.4% over 30 days and 44.3% over 1 year, which may have changed how some investors think about both its potential and its risks. Over the past year, Johnson & Johnson has remained in focus as a large healthcare name. Investors have been watching how it...",
        "pubDate": "2026-01-07T01:08:18Z",
        "displayTime": "2026-01-07T01:08:18Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VmOStVnJjLnU3xikg4stLA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/trESudVvS0UypUeXuQ_Yww--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-still-attractive-010818834.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-still-attractive-010818834.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T08:55:00+00:00",
    "headline": "The Smartest Dividend Stocks to Buy With $3,000 Right Now",
    "summary": "It's not too late to reshape and optimize your portfolio for what could be a very different market environment than last year's.",
    "url": "https://www.fool.com/investing/2026/01/07/the-smartest-dividend-stocks-to-buy-with-3000-righ/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "efe0d6ed-e5aa-307f-9dc7-2882ef79d4cb",
      "content": {
        "id": "efe0d6ed-e5aa-307f-9dc7-2882ef79d4cb",
        "contentType": "STORY",
        "title": "The Smartest Dividend Stocks to Buy With $3,000 Right Now",
        "description": "",
        "summary": "It's not too late to reshape and optimize your portfolio for what could be a very different market environment than last year's.",
        "pubDate": "2026-01-07T08:55:00Z",
        "displayTime": "2026-01-07T08:55:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/364a93a551b27f937402faa694badf85",
          "originalWidth": 1400,
          "originalHeight": 895,
          "caption": "Small sign reading \"dividends\" sitting on a desk.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/b3wjq8FDoY0yNaW6EnQEvw--~B/aD04OTU7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/364a93a551b27f937402faa694badf85.cf.webp",
              "width": 1400,
              "height": 895,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iCOIlQdfHUeR2hG3j7JySg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/364a93a551b27f937402faa694badf85.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/07/the-smartest-dividend-stocks-to-buy-with-3000-righ/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/smartest-dividend-stocks-buy-3-085500828.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "DLR"
            },
            {
              "symbol": "MCD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T08:53:34+00:00",
    "headline": "Bayer's Monsanto Sues Pfizer, Over COVID Vaccine Makers Over mRNA Technology Patents",
    "summary": "Bayer's Monsanto unit filed patent infringement lawsuits Tuesday against COVID-19 vaccine makers Pfi",
    "url": "https://finance.yahoo.com/news/bayer-apos-monsanto-sues-pfizer-085334049.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "9fdc73e8-e2d5-3cd1-ae33-97a55643e795",
      "content": {
        "id": "9fdc73e8-e2d5-3cd1-ae33-97a55643e795",
        "contentType": "STORY",
        "title": "Bayer's Monsanto Sues Pfizer, Over COVID Vaccine Makers Over mRNA Technology Patents",
        "description": "",
        "summary": "Bayer's Monsanto unit filed patent infringement lawsuits Tuesday against COVID-19 vaccine makers Pfi",
        "pubDate": "2026-01-07T08:53:34Z",
        "displayTime": "2026-01-07T08:53:34Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bayer-apos-monsanto-sues-pfizer-085334049.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bayer-apos-monsanto-sues-pfizer-085334049.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BAYRY"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "BNTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T10:07:16+00:00",
    "headline": "Update: Bayer's Monsanto Sues Pfizer, Over COVID Vaccine Makers Over mRNA Technology Patents",
    "summary": "(Updates with BioNTech response in the sixth paragraph.) Bayer's Monsanto unit filed patent infri",
    "url": "https://finance.yahoo.com/news/bayer-apos-monsanto-sues-pfizer-100716677.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "775ea529-c935-3e25-afbf-8155fe883f52",
      "content": {
        "id": "775ea529-c935-3e25-afbf-8155fe883f52",
        "contentType": "STORY",
        "title": "Update: Bayer's Monsanto Sues Pfizer, Over COVID Vaccine Makers Over mRNA Technology Patents",
        "description": "",
        "summary": "(Updates with BioNTech response in the sixth paragraph.) Bayer's Monsanto unit filed patent infri",
        "pubDate": "2026-01-07T10:07:16Z",
        "displayTime": "2026-01-07T10:07:16Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bayer-apos-monsanto-sues-pfizer-100716677.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bayer-apos-monsanto-sues-pfizer-100716677.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BAYRY"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "BNTX"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T13:00:00+00:00",
    "headline": "Johnson & Johnson Submits OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration",
    "summary": "NEW BRUNSWICK, N.J., January 07, 2026--Johnson & Johnson today announced that the company has submitted the OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration (FDA) in an application for De Novo classification. Leveraging data from the Investigational Device Exemption (IDE) study, the company has applied for marketing authorization in multiple procedures in general surgery within the upper abdomen.",
    "url": "https://finance.yahoo.com/news/johnson-johnson-submits-ottava-robotic-130000508.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "74b1513f-fb99-305d-ac62-4f0cc0ac2b32",
      "content": {
        "id": "74b1513f-fb99-305d-ac62-4f0cc0ac2b32",
        "contentType": "STORY",
        "title": "Johnson & Johnson Submits OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration",
        "description": "",
        "summary": "NEW BRUNSWICK, N.J., January 07, 2026--Johnson & Johnson today announced that the company has submitted the OTTAVA™ Robotic Surgical System to the U.S. Food and Drug Administration (FDA) in an application for De Novo classification. Leveraging data from the Investigational Device Exemption (IDE) study, the company has applied for marketing authorization in multiple procedures in general surgery within the upper abdomen.",
        "pubDate": "2026-01-07T13:00:00Z",
        "displayTime": "2026-01-07T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/a7e7ac6afc410f8bc852ca7060716773",
          "originalWidth": 2404,
          "originalHeight": 224,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/t0_k1jTMBp5xFo.N9bfxPQ--~B/aD0yMjQ7dz0yNDA0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a7e7ac6afc410f8bc852ca7060716773.cf.webp",
              "width": 2404,
              "height": 224,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/k2cGqWAdnfqW4DWqlwdo6Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a7e7ac6afc410f8bc852ca7060716773.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-submits-ottava-robotic-130000508.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-submits-ottava-robotic-130000508.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T13:33:00+00:00",
    "headline": "Amgen Buys Dark Blue Therapeutics to Strengthen Oncology Pipeline",
    "summary": "AMGN's $840M buyout of Dark Blue Therapeutics adds a preclinical AML degrader, bolstering its oncology pipeline.",
    "url": "https://finance.yahoo.com/news/amgen-buys-dark-blue-therapeutics-133300371.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "64d7c3e3-e262-320d-ab36-8fc7a42a2056",
      "content": {
        "id": "64d7c3e3-e262-320d-ab36-8fc7a42a2056",
        "contentType": "STORY",
        "title": "Amgen Buys Dark Blue Therapeutics to Strengthen Oncology Pipeline",
        "description": "",
        "summary": "AMGN's $840M buyout of Dark Blue Therapeutics adds a preclinical AML degrader, bolstering its oncology pipeline.",
        "pubDate": "2026-01-07T13:33:00Z",
        "displayTime": "2026-01-07T13:33:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/65410c79c0b8184da264ed17fda575ce",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tqYKNu6hTDA8V3302r2RBA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/65410c79c0b8184da264ed17fda575ce.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pyTd88a7yLXpjgTzs.cKAA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/65410c79c0b8184da264ed17fda575ce.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/amgen-buys-dark-blue-therapeutics-133300371.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amgen-buys-dark-blue-therapeutics-133300371.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T14:00:04+00:00",
    "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
    "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
    "url": "https://finance.yahoo.com/news/2-medical-stocks-could-beat-140004950.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "d8f9896b-1253-37e5-9d92-16debed54264",
      "content": {
        "id": "d8f9896b-1253-37e5-9d92-16debed54264",
        "contentType": "STORY",
        "title": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
        "description": "",
        "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
        "pubDate": "2026-01-07T14:00:04Z",
        "displayTime": "2026-01-07T14:00:04Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/078b2d95159d12a337f09f2519ff10ba",
          "originalWidth": 900,
          "originalHeight": 745,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/J2T_cDhaoaaQj0soPS_nNw--~B/aD03NDU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/078b2d95159d12a337f09f2519ff10ba.cf.webp",
              "width": 900,
              "height": 745,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sWMlcbg78JI.iCrZWAER9Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/078b2d95159d12a337f09f2519ff10ba.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/2-medical-stocks-could-beat-140004950.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-medical-stocks-could-beat-140004950.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T04:49:58+00:00",
    "headline": "Stereotaxis wins FDA approval for robotically navigated ablation catheter",
    "summary": "Stereotaxis’ CEO said the company has been “hampered clinically, commercially and strategically” by its prior dependence on a J&J catheter.",
    "url": "https://www.medtechdive.com/news/stereotaxis-fda-approval-robot-catheter/808941/",
    "source": "MedTech Dive",
    "provider": "yfinance",
    "raw": {
      "id": "ad7440b0-0f2b-3f8a-b278-fda1a2ab18ba",
      "content": {
        "id": "ad7440b0-0f2b-3f8a-b278-fda1a2ab18ba",
        "contentType": "STORY",
        "title": "Stereotaxis wins FDA approval for robotically navigated ablation catheter",
        "description": "",
        "summary": "Stereotaxis’ CEO said the company has been “hampered clinically, commercially and strategically” by its prior dependence on a J&J catheter.",
        "pubDate": "2026-01-07T04:49:58Z",
        "displayTime": "2026-01-07T04:49:58Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/medtech_dive_335/750fdf53cb35947d5f0ce8a43a826421",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "MedTech Dive, an Industry Dive publication",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CfiwZcqajD6GIrfQSU8QEw--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/medtech_dive_335/750fdf53cb35947d5f0ce8a43a826421.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jrfLJxLAsCtfuwsqFT5_ww--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/medtech_dive_335/750fdf53cb35947d5f0ce8a43a826421.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MedTech Dive",
          "url": "https://medtechdive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.medtechdive.com/news/stereotaxis-fda-approval-robot-catheter/808941/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/stereotaxis-wins-fda-approval-robotically-044958616.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "STXS"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T17:17:00+00:00",
    "headline": "Facial Skincare Market by Type, Gender, Distribution Channel, Countries and Companies Analysis 2025-2033 Featuring L'Oreal, P&G, Oriflamme, Unilever, Estee Lauder Company, Johnson & Johnson",
    "summary": "Facial Skincare Market Facial Skincare Market Dublin, Jan. 07, 2026 (GLOBE NEWSWIRE) -- The \"Facial Skincare Market by Type, Gender, Distribution Channel, Countries and Companies Analysis 2025-2033\" has been added to ResearchAndMarkets.com's offering. The worldwide facial skincare market is anticipated to hit US$ 158.63 billion in 2033, increasing from US$ 98.56 billion in 2024, growing at a CAGR of 5.43% during 2025-2033. Increased consumer knowledge, the need for anti-aging, and new developmen",
    "url": "https://finance.yahoo.com/news/facial-skincare-market-type-gender-171700603.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "c359aaf1-908c-372c-a5c6-34bc796df51f",
      "content": {
        "id": "c359aaf1-908c-372c-a5c6-34bc796df51f",
        "contentType": "STORY",
        "title": "Facial Skincare Market by Type, Gender, Distribution Channel, Countries and Companies Analysis 2025-2033 Featuring L'Oreal, P&G, Oriflamme, Unilever, Estee Lauder Company, Johnson & Johnson",
        "description": "",
        "summary": "Facial Skincare Market Facial Skincare Market Dublin, Jan. 07, 2026 (GLOBE NEWSWIRE) -- The \"Facial Skincare Market by Type, Gender, Distribution Channel, Countries and Companies Analysis 2025-2033\" has been added to ResearchAndMarkets.com's offering. The worldwide facial skincare market is anticipated to hit US$ 158.63 billion in 2033, increasing from US$ 98.56 billion in 2024, growing at a CAGR of 5.43% during 2025-2033. Increased consumer knowledge, the need for anti-aging, and new developmen",
        "pubDate": "2026-01-07T17:17:00Z",
        "displayTime": "2026-01-07T17:17:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/e79cb953477054ee8c92a9bef42de83d",
          "originalWidth": 600,
          "originalHeight": 400,
          "caption": "Facial Skincare Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PPQXvAf8f2ysAklVFZGtGg--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/e79cb953477054ee8c92a9bef42de83d.cf.webp",
              "width": 600,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/j7d767vhFbH7E5FwQzV_lQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/e79cb953477054ee8c92a9bef42de83d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/facial-skincare-market-type-gender-171700603.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/facial-skincare-market-type-gender-171700603.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LRLCF"
            },
            {
              "symbol": "PG"
            },
            {
              "symbol": "UL"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T17:42:28+00:00",
    "headline": "J&J’s Imaavy posts win in Phase II SLE trial",
    "summary": "Imaavy will now progress to Phase III in SLE, though it will face strong competition from SLE market leader, Benlysta, if approved.",
    "url": "https://www.clinicaltrialsarena.com/news/johnson-johnson-imaavy-phase-iib-sle/",
    "source": "Clinical Trials Arena",
    "provider": "yfinance",
    "raw": {
      "id": "656b6bce-5404-3e01-bfc0-ce98a4074eea",
      "content": {
        "id": "656b6bce-5404-3e01-bfc0-ce98a4074eea",
        "contentType": "STORY",
        "title": "J&J’s Imaavy posts win in Phase II SLE trial",
        "description": "",
        "summary": "Imaavy will now progress to Phase III in SLE, though it will face strong competition from SLE market leader, Benlysta, if approved.",
        "pubDate": "2026-01-07T17:42:28Z",
        "displayTime": "2026-01-07T17:42:28Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/clinical_trials_arena_396/9a804e8dafc13f9671b90b5bf2ede1a5",
          "originalWidth": 1000,
          "originalHeight": 537,
          "caption": "Johnson & Johnson's Imaavy (nipocalimab) met its primary and secondary trial endpoints in the Phase IIb JASMINE study in systemic lupus erythematosus (SLE). Image credit: StanislavSukhin via ShutterStock.com.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2IMZvmRIVmpqbb4HUeYuwQ--~B/aD01Mzc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/9a804e8dafc13f9671b90b5bf2ede1a5.cf.webp",
              "width": 1000,
              "height": 537,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/z8D5Q74PdYstus7CV6laGw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/clinical_trials_arena_396/9a804e8dafc13f9671b90b5bf2ede1a5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Clinical Trials Arena",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.clinicaltrialsarena.com/news/johnson-johnson-imaavy-phase-iib-sle/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/j-j-imaavy-posts-win-174228725.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-07T16:34:00+00:00",
    "headline": "The Dow Is Cruising Past Milestones. What Comes After 50,000.",
    "summary": "The Dow Jones Industrial Average is on the verge of another big milestone and could continue to climb as the rally broadens.",
    "url": "https://www.barrons.com/articles/dow-50k-stocks-rally-cecd3771?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "02128e1c-c43c-3286-938a-9814ecb4923e",
      "content": {
        "id": "02128e1c-c43c-3286-938a-9814ecb4923e",
        "contentType": "STORY",
        "title": "The Dow Is Cruising Past Milestones. What Comes After 50,000.",
        "description": "",
        "summary": "The Dow Jones Industrial Average is on the verge of another big milestone and could continue to climb as the rally broadens.",
        "pubDate": "2026-01-07T16:34:00Z",
        "displayTime": "2026-01-07T16:34:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/02128e1c-c43c-3286-938a-9814ecb4923e/the-dow-is-cruising-past.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/5bebe976fdc660bb6e5dfa4e05f0a39d",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hZnuxEixFvVWVRrPOjVfRQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/5bebe976fdc660bb6e5dfa4e05f0a39d.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GQ90KaVHpXRatLijk7bmJQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/5bebe976fdc660bb6e5dfa4e05f0a39d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/dow-50k-stocks-rally-cecd3771?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]